Thus this model provides us with a novel in vivo tool to explore the mechanisms leading to NIS suppression, and to attempt to pharmacologically restore radioiodine sensitivity, as recently described in a model of papillary and poorly differentiated BRAFV600E-dependent thyroid carcinoma [52]. This evidence concerns the gene SLC5A5 and thyroid gland carcinoma.